Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Clara Martinez-Vila
affiliation not provided to SSRN
Contact
affiliation not provided to SSRN
Email
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
43
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Real-World Outcomes with Ipilimumab and Nivolumab in Advanced Melanoma: A Multicentre Retrospective Study
Number of pages: 20
Posted: 31 Mar 2022
Patricio Serra-Bellver
,
Judith M. Versluis
,
Honey K. Oberoi
,
Cong Zhou
,
Timothy D. Slattery
,
Yasir Khan
,
James R. Patrinely
,
Ines Pires da Silva
, Clara Martinez-Vila,
Natalie Cook
,
Donna Graham
,
Matteo Carlino
,
Alexander M. Menzies
,
Ana M. Arance
,
Douglas B. Douglas
,
Georgina V. Long
,
Lisa Pickering
,
James M. G. Larkin
,
Christian U. Blank
and
Paul Lorigan
Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
,
affiliation not provided to SSRN
, The University of Sydney - Melanoma Institute Australia,
affiliation not provided to SSRN
, The University of Manchester, The Christie NHS Foundation Trust, Blacktown Hospital, The University of Sydney - Melanoma Institute Australia, Hospital of Barcelona, Vanderbilt University - Vanderbilt-Ingram Cancer Center, The University of Sydney - Melanoma Institute Australia, Royal Marsden NHS Foundation Trust - Renal and Skin Units, NHS Foundation Trust - Royal Marsden Hospital, Netherlands Cancer Institute and The University of Manchester
Downloads
43
(1,145,425)
View PDF
Download
Abstract:
melanoma, real-world, ipilimumab+nivolumab, immunotherapy
Feedback